| Literature DB >> 28316069 |
Clare Frobisher1, Emma R Lancashire2, Helen Jenkinson3, David L Winter1, Julie Kelly1, Raoul C Reulen1, Michael M Hawkins1.
Abstract
The British Childhood Cancer Survivor Study (BCCSS) provides the first detailed investigation of employment and occupation to be undertaken in a large population-based cohort. Previous studies have been limited by design issues such as using small numbers of survivors with specific diagnoses, and involved limited assessment of employment status and occupational level. The BCCSS includes 17,981 5-year survivors of childhood cancer. Employment status and occupational level were ascertained by questionnaire from eligible survivors (n = 14,836). Multivariate logistic regression was used to explore factors associated with employment and occupation, and to compare survivors to their demographic peers in the general population. Employment status was available for 10,257 survivors. Gender, current age, cancer type, radiotherapy, age at diagnosis and epilepsy were consistently associated with being: employed; unable to work; in managerial or non-manual occupations. Overall, survivors were less likely to be working than expected (OR (99% CI): 0.89 (0.81-0.98)), and this deficit was greatest for irradiated CNS neoplasm survivors (0.34 (0.28-0.41)). Compared to the general population, survivors were fivefold more likely to be unable to work due to illness/disability; the excess was 15-fold among CNS neoplasm survivors treated with radiotherapy. Overall survivors were less likely to be in managerial occupations than expected (0.85 (0.77-0.94)). However, bone sarcoma survivors were more likely to be in these occupations than expected (1.37 (1.01-1.85)) and also similarly for non-manual occupations (1.90 (1.37-2.62)). Survivors of retinoblastoma (1.55 (1.20-2.01)) and 'other' neoplasm group (1.62 (1.30-2.03)) were also more likely to be in non-manual occupations than expected.Entities:
Keywords: childhood cancer; economic status; employment; occupation; social outcome; survivorship
Mesh:
Year: 2017 PMID: 28316069 PMCID: PMC5434894 DOI: 10.1002/ijc.30696
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396
Figure 1(a) Flow chart detailing the numbers involved at each stage from the BCCSS. (b) Flow chart detailing the numbers involved at each stage from the General Household Survey (GHS) for the year 2002.
Frequency of survivors for the outcomes being: employed, unemployed; and unable to work due to illness and disability, and the corresponding ORs (99% CIs) from multivariable logistic regression for these outcomes with selected demographic, cancer and health related factors in the childhood cancer survivors
| Survivors who were employed | Survivors who were unemployed and looking for work | Survivors unable to work due to illness or disability | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Factor | Total number of survivors | % of survivors who were employed | Adjusted odds ratio for being employed | 99% CI | % of survivors who were unemployed and looking for work | Adjusted odds ratio for being unemployed | 99% CI | % of survivors unable to work due to illness/disability | Adjusted odds ratio for being unable to work due to illness/disability | 99% CI |
|
| ||||||||||
| Male | 5256 | 67.2 | 1.00 | 5.2 | 1.00 | 9.4 | 1.00 | |||
| Female | 5001 | 57.7 | 0.58 | 0.51–0.66 | 3.4 | 0.63 | 0.48–0.82 | 12.0 | 1.33 | 1.09–1.62 |
|
| <0.001 | <0.001 | <0.001 | |||||||
|
| ||||||||||
| 16–19 | 1991 | 24.9 | 1.00 | 5.2 | 1.00 | 2.7 | 1.00 | |||
| 20–24 | 1712 | 63.4 | 5.64 | 4.60–6.92 | 6.7 | 1.32 | 0.90–1.94 | 8.4 | 4.35 | 2.65–7.12 |
| 25–29 | 1877 | 76.7 | 11.76 | 9.42–14.68 | 4.1 | 0.74 | 0.47–1.15 | 10.9 | 5.43 | 3.35–8.82 |
| 30–34 | 1668 | 74.8 | 10.87 | 8.64–13.67 | 4.0 | 0.72 | 0.46–1.15 | 12.3 | 6.31 | 3.87–10.30 |
| 35–39 | 1255 | 75.4 | 11.44 | 8.88–14.73 | 3.0 | 0.62 | 0.36–1.06 | 13.2 | 6.81 | 4.10–11.31 |
| 40–44 | 744 | 71.0 | 9.10 | 6.82–12.14 | 3.0 | 0.51 | 0.26–1.01 | 18.2 | 10.54 | 6.23–17.85 |
| 45–49 | 485 | 73.0 | 10.50 | 7.41–14.87 | 2.9 | 0.57 | 0.25–1.27 | 18.6 | 10.14 | 5.69–18.05 |
| 50–54 | 333 | 67.9 | 7.96 | 5.43–11.67 | 2.4 | 0.44 | 0.15–1.26 | 18.9 | 10.71 | 5.77–19.89 |
| ≥ 55 | 192 | 47.9 | 3.07 | 1.94–4.88 | 1.6 | 0.11 | 0.01–1.53 | 18.8 | 12.27 | 5.93–25.39 |
|
| <0.001 | <0.001 | <0.001 | |||||||
|
| <0.001 (<0.001) | <0.001 (0.072) | <0.001 (<0.001) | |||||||
|
| ||||||||||
| CNS neoplasm | 2153 | 51.5 | 1.00 | 5.2 | 1.00 | 26.1 | 1.00 | |||
| Leukaemia | 2819 | 60.0 | 1.57 | 1.28–1.92 | 5.0 | 0.92 | 0.61–1.38 | 6.4 | 0.51 | 0.38–0.69 |
| Hodgkin's lymphoma | 724 | 81.1 | 2.03 | 1.49–2.78 | 3.7 | 0.84 | 0.45–1.58 | 4.8 | 0.28 | 0.16–0.47 |
| Non‐hodgkin's lymphoma | 530 | 74.5 | 1.79 | 1.29–2.48 | 3.4 | 0.64 | 0.31–1.34 | 6.0 | 0.43 | 0.25–0.73 |
| Neuroblastoma | 420 | 54.0 | 1.46 | 1.01–2.10 | 4.5 | 1.00 | 0.46–2.15 | 5.7 | 0.43 | 0.22–0.81 |
| Retinoblastoma | 692 | 62.7 | 2.38 | 1.72–3.28 | 5.8 | 1.32 | 0.72–2.41 | 7.1 | 0.21 | 0.13–0.35 |
| Wilms' tumour | 954 | 63.0 | 1.53 | 1.17–2.00 | 3.5 | 0.74 | 0.41–1.32 | 5.4 | 0.41 | 0.26–0.65 |
| Bone sarcoma | 389 | 72.8 | 1.29 | 0.91–1.85 | 1.8 | 0.45 | 0.16–1.28 | 10.8 | 0.78 | 0.48–1.30 |
| Soft tissue sarcomas | 706 | 67.1 | 1.60 | 1.20–2.13 | 3.5 | 0.74 | 0.39–1.40 | 8.6 | 0.60 | 0.39–0.91 |
| Other neoplasm | 870 | 70.5 | 1.92 | 1.46–2.51 | 3.0 | 0.67 | 0.35–1.25 | 6.6 | 0.37 | 0.24–0.57 |
|
| <0.001 | 0.155 | <0.001 | |||||||
|
| ||||||||||
| Surgery No | 3355 | 70.5 | 1.00 | 4.5 | 1.00 | 9.2 | 1.00 | |||
| Yes | 4185 | 68.1 | 0.79 | 0.64–0.96 | 3.7 | 0.94 | 0.61–1.46 | 15.0 | 1.46 | 1.09–1.94 |
|
| 0.002 | 0.728 | <0.001 | |||||||
| Radiotherapy (RT) No RT | 2176 | 69.8 | 1.00 | 3.3 | 1.00 | 10.4 | 1.00 | |||
| Non‐cranial RT | 2231 | 76.6 | 0.96 | 0.77–1.19 | 3.0 | 1.10 | 0.67–1.81 | 9.6 | 1.49 | 1.08–2.05 |
| Cranial RT | 2909 | 62.6 | 0.62 | 0.50–0.77 | 5.5 | 1.38 | 0.85–2.22 | 16.5 | 2.51 | 1.84–3.41 |
|
| <0.001 | 0.200 | <0.001 | |||||||
| Chemotherapy No | 3268 | 66.0 | 1.00 | 3.6 | 1.00 | 17.1 | 1.00 | |||
| Yes | 3834 | 71.4 | 1.09 | 0.88–1.34 | 4.4 | 0.94 | 0.60–1.46 | 8.0 | 0.82 | 0.61–1.10 |
|
| 0.290 | 0.701 | 0.086 | |||||||
|
| ||||||||||
| 0 | 834 | 52.6 | 1.00 | 4.1 | 1.00 | 7.6 | 1.00 | |||
| 1–4 | 3900 | 53.9 | 1.07 | 0.83–1.40 | 5.0 | 1.37 | 0.77–2.41 | 9.1 | 1.10 | 0.69–1.73 |
| 5–9 | 2719 | 66.8 | 1.41 | 1.05–1.88 | 4.8 | 1.43 | 0.77–2.69 | 11.6 | 0.79 | 0.48–1.30 |
| 10–14 | 2804 | 73.4 | 1.43 | 1.05–1.94 | 3.1 | 1.20 | 0.61–2.36 | 13.0 | 0.70 | 0.42–1.16 |
|
| <0.001 | 0.329 | <0.001 | |||||||
|
| <0.001 (0.076) | 0.939 (0.180) | <0.001 (0.153) | |||||||
|
| ||||||||||
| No | 9648 | 62.9 | 1.00 | 4.4 | 1.00 | 10.0 | 1.00 | |||
| Yes | 609 | 57.6 | 0.68 | 0.52–0.88 | 3.9 | 1.06 | 0.58–1.93 | 21.7 | 1.63 | 1.17–2.27 |
|
| <0.001 | 0.806 | <0.001 | |||||||
|
| ||||||||||
| No | 9030 | 65.8 | 1.00 | 4.2 | 1.00 | 7.3 | 1.00 | |||
| Yes | 980 | 38.2 | 0.33 | 0.27–0.42 | 5.4 | 1.31 | 0.85–2.01 | 38.1 | 4.89 | 3.84–6.23 |
|
| <0.001 | 0.111 | <0.001 | |||||||
|
| ||||||||||
| No | 9002 | 63.9 | 1.00 | 4.3 | 1.00 | 9.1 | 1.00 | |||
| Yes | 965 | 53.1 | 0.75 | 0.61–0.93 | 4.4 | 1.03 | 0.65–1.63 | 22.9 | 1.77 | 1.35–2.32 |
|
| <0.001 | 0.880 | <0.001 | |||||||
|
| ||||||||||
| No | 8684 | 65.5 | 1.00 | 4.1 | 1.00 | 8.0 | 1.00 | |||
| Yes | 1297 | 45.6 | 0.44 | 0.36–0.54 | 5.9 | 1.34 | 0.89–2.01 | 26.4 | 3.00 | 2.33–3.86 |
|
| <0.001 | 0.069 | <0.001 | |||||||
|
| ||||||||||
| No | 8848 | 64.1 | 1.00 | 4.2 | 1.00 | 9.5 | 1.00 | |||
| Yes | 1334 | 53.3 | 0.69 | 0.58–0.84 | 5.0 | 1.07 | 0.73–1.57 | 17.7 | 1.72 | 1.33–2.22 |
|
| <0.001 | 0.649 | <0.001 | |||||||
For all factors in the above table, with the exception of the treatment factors (surgery, chemotherapy and radiotherapy), the multivariable logistic regression included all factors without surgery, chemotherapy and radiotherapy and the resulting odds ratios and p values are from this model. For the treatment factors, the multivariable logistic regression included all factors with the exception of cancer type and the resulting odds ratios and p values for the treatment factors are from this model.
Odds ratios (OR) and 99% confidence intervals (CI) for adult survivors of childhood cancer who were: employed; unemployed; unable to work due to illness or disability; a student; caring for home or family compared to the general population of Britain, overall and by childhood cancer type, survivors treated with and without radiotherapy are considered separately for CNS neoplasmsa
| Employed | Unemployed and looking for work | Unable to work due to illness or disability | Student | Caring for home or family | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer type | OR | (99% CI) |
| OR | (99% CI) |
| OR | (99% CI) |
| OR | (99% CI) |
| OR | (99% CI) |
|
| All cancer types | 0.89 | (0.81–0.98) | 0.002 | 0.89 | (0.72–1.09) | 0.137 | 4.99 | (4.06–6.13) | <0.0005 | 1.13 | (0.97–1.32) | 0.043 | 0.63 | (0.53–0.74) | <0.0005 |
| Leukaemia | 1.13 | (0.96–1.34) | 0.055 | 0.99 | (0.72–1.37) | 0.955 | 4.41 | (3.07–6.32) | <0.0005 | 0.78 | (0.61–0.99) | 0.007 | 0.60 | (0.45–0.82) | <0.0005 |
| Hodgkin's lymphoma | 1.55 | (1.18–2.04) | <0.0005 | 0.84 | (0.50–1.44) | 0.413 | 1.49 | (0.92–2.41) | 0.033 | 0.81 | (0.50–1.33) | 0.272 | 0.63 | (0.37–1.06) | 0.022 |
| Non‐Hodgkin's lymphoma | 1.39 | (1.04–1.85) | 0.004 | 0.71 | (0.37–1.34) | 0.162 | 2.24 | (1.34–3.75) | <0.0005 | 0.88 | (0.59–1.30) | 0.395 | 0.76 | (0.42–1.37) | 0.235 |
| CNS neoplasm | 0.34 | (0.28–0.41) | <0.0005 | 1.50 | (1.04–2.18) | 0.005 | 15.40 | (11.94–19.85) | <0.0005 | 0.69 | (0.45–1.04) | 0.020 | 0.45 | (0.29–0.71) | <0.0005 |
| RT=No | 0.64 | (0.49–0.82) | <0.0005 | 0.74 | (0.40–1.38) | 0.214 | 8.29 | (6.08–11.31) | <0.0005 | 0.93 | (0.58–1.49) | 0.679 | 0.86 | (0.56–1.33) | 0.373 |
| Neuroblastoma | 0.83 | (0.62–1.11) | 0.098 | 0.86 | (0.45–1.63) | 0.537 | 2.93 | (1.62–5.30) | <0.0005 | 1.64 | (1.15–2.34) | <0.0005 | 0.65 | (0.34–1.24) | 0.087 |
| Retinoblastoma | 0.94 | (0.74–1.20) | 0.534 | 1.30 | (0.83–2.05) | 0.137 | 2.69 | (1.76–4.11) | <0.0005 | 1.50 | (1.10–2.05) | 0.001 | 0.62 | (0.39–1.00) | 0.010 |
| Wilms tumour | 1.04 | (0.84–1.27) | 0.668 | 0.67 | (0.41–1.09) | 0.036 | 2.67 | (1.73–4.11) | <0.0005 | 1.40 | (1.07–1.84) | 0.001 | 0.65 | (0.43–0.98) | 0.007 |
| Bone sarcomas | 1.16 | (0.82–1.66) | 0.274 | 0.41 | (0.15–1.12) | 0.023 | 3.98 | (2.49–6.38) | <0.0005 | 0.59 | (0.29–1.18) | 0.049 | 0.92 | (0.55–1.56) | 0.694 |
| Soft tissue sarcomas | 1.14 | (0.89–1.45) | 0.185 | 0.74 | (0.43–1.29) | 0.164 | 3.41 | (2.29–5.08) | <0.0005 | 1.15 | (0.82–1.61) | 0.280 | 0.54 | (0.32–0.92) | 0.003 |
| Other neoplasm | 1.30 | (1.04–1.64) | 0.003 | 0.65 | (0.38–1.11) | 0.040 | 2.59 | (1.74–3.87) | <0.0005 | 1.06 | (0.77–1.45) | 0.659 | 0.69 | (0.46–1.02) | 0.013 |
Population data from the GHS (2002) was used for the reference group.
Excludes survivors for whom no record is available regarding radiotherapy.
There were insufficient leukaemia survivors known to have been unexposed to cranial irradiation for separate meaningful assessment.
On using the False Discovery Rate method the corrected p values indicated that the null hypothesis was not rejected for these particular tests.
Frequency of survivors for the outcomes being classified to: managerial/professional occupation; and to non‐manual occupation, and the corresponding ORs (99% CIs) from multivariable logistic regression for these outcomes with selected demographic, cancer and health related factors in the childhood cancer survivors
| Managerial/professional occupational level | Non‐manual occupational level | ||||||
|---|---|---|---|---|---|---|---|
| Factor | Total number of survivors | % of survivors who were classified to this level | Adjusted odds ratio for being classified to this level | 99% CI | % of survivors who were classified to this level | Adjusted odds ratio for being classified to this level | 99% CI |
|
| |||||||
| Male | 4014 | 32.5 | 1.00 | 53.2 | 1.00 | ||
| Female | 3685 | 29.0 | 0.80 | 0.69–0.91 | 58.1 | 1.15 | 1.01–1.31 |
|
| <0.001 | 0.005 | |||||
|
| |||||||
| 16–19 | 550 | 3.8 | 1.00 | 22.7 | 1.00 | ||
| 20–24 | 1234 | 23.3 | 7.73 | 4.17–14.32 | 49.0 | 3.27 | 2.39–4.48 |
| 25–29 | 1640 | 36.5 | 13.45 | 7.32–24.71 | 60.2 | 4.77 | 3.50–6.50 |
| 30–34 | 1493 | 34.2 | 12.55 | 6.81–23.11 | 59.8 | 4.69 | 3.42–6.42 |
| 35–39 | 1156 | 34.9 | 12.60 | 6.80–23.36 | 59.7 | 4.52 | 3.26–6.26 |
| 40–44 | 680 | 37.4 | 14.04 | 7.45–26.44 | 61.8 | 4.77 | 3.33–6.82 |
| 45–49 | 448 | 33.5 | 10.77 | 5.59–20.76 | 61.2 | 4.41 | 2.98–6.52 |
| 50–54 | 315 | 28.6 | 8.74 | 4.40–17.38 | 56.8 | 3.47 | 2.26–5.31 |
| ≥ 55 | 183 | 31.7 | 10.49 | 4.98–22.09 | 56.8 | 3.69 | 2.20–6.21 |
|
| <0.001 | <0.001 | |||||
|
| <0.001 (<0.001) | <0.001 (<0.001) | |||||
|
| |||||||
| CNS neoplasm | 1528 | 21.9 | 1.00 | 48.4 | 1.00 | ||
| Leukaemia | 1943 | 25.0 | 1.34 | 1.06–1.71 | 47.5 | 1.15 | 0.93–1.42 |
| Hodgkin's lymphoma | 660 | 37.4 | 1.59 | 1.20–2.12 | 57.9 | 1.23 | 0.94–1.60 |
| Non‐Hodgkin's lymphoma | 450 | 34.9 | 1.66 | 1.20–2.28 | 59.1 | 1.50 | 1.11–2.02 |
| Neuroblastoma | 270 | 33.7 | 2.30 | 1.49–3.54 | 57.8 | 2.01 | 1.34–3.02 |
| Retinoblastoma | 528 | 38.1 | 2.79 | 1.97–3.97 | 65.2 | 2.36 | 1.69–3.29 |
| Wilms' tumour | 706 | 32.9 | 2.09 | 1.54–2.84 | 58.8 | 1.95 | 1.48–2.57 |
| Bone sarcoma | 347 | 42.7 | 2.20 | 1.56–3.10 | 71.8 | 2.43 | 1.69–3.48 |
| Soft tissue sarcomas | 557 | 37.9 | 2.12 | 1.57–2.86 | 59.6 | 1.69 | 1.27–2.25 |
| Other neoplasm | 710 | 37.5 | 1.98 | 1.50–2.62 | 66.3 | 2.07 | 1.58–2.71 |
|
| <0.001 | <0.001 | |||||
|
| |||||||
| Surgery No | 2753 | 29.7 | 1.00 | 53.7 | 1.00 | ||
| Yes | 3567 | 34.1 | 1.13 | 0.93–1.36 | 59.9 | 1.10 | 0.91–1.32 |
|
| 0.108 | 0.207 | |||||
| Radiotherapy (RT) No RT | 1836 | 34.2 | 1.00 | 60.6 | 1.00 | ||
| Non‐cranial RT | 2037 | 39.7 | 1.16 | 0.96–1.41 | 64.9 | 1.14 | 0.94–1.39 |
| Cranial RT | 2250 | 23.6 | 0.65 | 0.52–0.82 | 47.5 | 0.63 | 0.52–0.78 |
|
| <0.001 | <0.001 | |||||
| Chemotherapy No | 2765 | 31.7 | 1.00 | 58.8 | 1.00 | ||
| Yes | 3164 | 32.3 | 1.27 | 1.04–1.55 | 55.8 | 1.16 | 0.95–1.40 |
|
| 0.002 | 0.054 | |||||
|
| |||||||
| 0 | 524 | 36.3 | 1.00 | 60.1 | 1.00 | ||
| 1–4 | 2484 | 25.0 | 0.79 | 0.59–1.08 | 49.2 | 0.88 | 0.65–1.18 |
| 5–9 | 2174 | 28.0 | 1.00 | 0.72–1.40 | 52.6 | 1.10 | 0.80–1.51 |
| 10–14 | 2517 | 37.9 | 1.34 | 0.95–1.87 | 63.4 | 1.47 | 1.06–2.04 |
|
| <0.001 | <0.001 | |||||
|
| <0.001 (<0.001) | <0.001 (0.005) | |||||
|
| |||||||
| No | 7209 | 30.7 | 1.00 | 55.3 | 1.00 | ||
| Yes | 490 | 32.2 | 0.99 | 0.75–1.31 | 59.2 | 1.06 | 0.81–1.38 |
|
| 0.922 | 0.595 | |||||
|
| |||||||
| No | 6982 | 32.1 | 1.00 | 56.6 | 1.00 | ||
| Yes | 586 | 18.6 | 0.57 | 0.42–0.78 | 45.4 | 0.70 | 0.54–0.89 |
|
| <0.001 | 0.002 | |||||
|
| |||||||
| No | 6805 | 31.6 | 1.00 | 56.3 | 1.00 | ||
| Yes | 695 | 26.6 | 0.83 | 0.65–1.07 | 52.5 | 0.88 | 0.71–1.11 |
|
| 0.0574 | 0.160 | |||||
|
| |||||||
| No | 6666 | 31.3 | 1.00 | 55.4 | 1.00 | ||
| Yes | 849 | 29.8 | 0.94 | 0.73–1.20 | 59.0 | 1.15 | 0.91–1.44 |
|
| 0.510 | 0.119 | |||||
|
| |||||||
| No | 6732 | 31.1 | 1.00 | 55.9 | 1.00 | ||
| Yes | 919 | 29.6 | 0.94 | 0.76–1.16 | 54.2 | 0.96 | 0.79–1.18 |
|
| 0.449 | 0.639 | |||||
Includes all survivors who are not a student and provided sufficient information on current or most recent employment to enable classification to one of the NSSEC occupational levels.
For all factors in the above table, with the exception of the treatment factors (surgery, chemotherapy and radiotherapy), the multivariable logistic regression included all factors without surgery, chemotherapy and radiotherapy and the resulting odds ratios and p values are from this model. For the treatment factors, the multivariable logistic regression included all factors with the exception of cancer type and the resulting odds ratios and p values for the treatment factors are from this model.
On using the False Discovery Rate method the corrected p values indicated that the null hypothesis was not rejected for this particular test of non‐linearity.
Odds ratios (OR) and 99% confidence intervals (CI) for adult survivors of childhood cancer being classified to a managerial or professional occupational level and also being classified to non‐manual occupational level using the National Statistics Socio‐economic Classification (NSSEC) compared to the general population of Britain, overall and by childhood cancer type, survivors treated with and without radiotherapy are considered separately for CNS neoplasmsa
| Those classified to the managerial/Professional occupational level |
Those classified to the non‐manual | |||||
|---|---|---|---|---|---|---|
| Cancer type | OR | (99% CI) |
| OR | (99% CI) |
|
| All cancer types | 0.85 | (0.77–0.94) | <0.0005 | 1.03 | (0.93–1.13) | 0.471 |
| Leukaemia | 0.68 | (0.56–0.82) | <0.0005 | 0.80 | (0.67–0.94) | <0.0005 |
| Hodgkin's lymphoma | 0.95 | (0.76–1.20) | 0.589 | 1.00 | (0.80–1.24) | 0.956 |
| Non‐Hodgkin's lymphoma | 0.94 | (0.71–1.23) | 0.540 | 1.18 | (0.91–1.54) | 0.105 |
| CNS neoplasm | 0.41 | (0.32–0.52) | <0.0005 | 0.57 | (0.46–0.70) | <0.0005 |
| RT=No | 0.59 | (0.45–0.78) | <0.0005 | 0.89 | (0.69–1.13) | 0.203 |
| Neuroblastoma | 1.08 | (0.75–1.56) | 0.589 | 1.24 | (0.87–1.77) | 0.119 |
| Retinoblastoma | 1.19 | (0.92–1.53) | 0.076 | 1.55 | (1.20–2.01) | <0.0005 |
| Wilms tumour | 0.96 | (0.77–1.21) | 0.682 | 1.23 | (0.98–1.53) | 0.017 |
| Bone sarcomas | 1.37 | (1.01–1.85) | 0.008 | 1.90 | (1.37–2.62) | <0.0005 |
| Soft tissue sarcomas | 1.14 | (0.89–1.46) | 0.177 | 1.20 | (0.95–1.53) | 0.047 |
| Other neoplasm | 1.18 | (0.95–1.48) | 0.049 | 1.62 | (1.30–2.03) | <0.0005 |
Population data from the GHS (2002) was used for the reference group.
Excludes survivors for whom no record is available regarding radiotherapy.
There were insufficient leukaemia survivors known to have been unexposed to cranial irradiation for separate meaningful assessment.
Excludes students and unemployed individuals but includes all other individuals who provided sufficient employment information to classify them according to NSSEC.
On using the False Discovery Rate method this association was no longer statistically significant.